123 related articles for article (PubMed ID: 7971494)
1. [Should hemostatic factors be considered in the prevention of cardiovascular disease?].
Musiał J; Duplaga M
Pol Tyg Lek; 1993 Aug 2-16; 48(31-33):699-702. PubMed ID: 7971494
[TBL] [Abstract][Full Text] [Related]
2. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Chapman MJ
Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
[TBL] [Abstract][Full Text] [Related]
3. [Role of the hemostasis in unstable angina pectoris].
Lisowski P; Małyszko J; Lisowska A; Czech B; Myśliwiec M; Jackowski R; Hirnle T
Pol Merkur Lekarski; 2004 May; 16(95):468-71. PubMed ID: 15518429
[TBL] [Abstract][Full Text] [Related]
4. [Role of the hemostatic system in pathogenesis of atherosclerosis as the main etiology of coronary ischemia] [corrected].
Lisowski P; Małyszko J; Lisowska A; Czech B; Myśliwiec M; Jackowski R; Hirnle T
Pol Merkur Lekarski; 2004 May; 16(95):465-7. PubMed ID: 15518428
[TBL] [Abstract][Full Text] [Related]
5. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
6. [Hemostatic anomalies and coronary risk].
de Lorgeril M; Renaud S
Rev Prat; 1992 Nov; 42(17):2136-40. PubMed ID: 1290035
[TBL] [Abstract][Full Text] [Related]
7. Coronary atherosclerosis. A multifactorial disease.
Badimon JJ; Fuster V; Chesebro JH; Badimon L
Circulation; 1993 Mar; 87(3 Suppl):II3-16. PubMed ID: 8443920
[TBL] [Abstract][Full Text] [Related]
8. Coronary atherothrombotic disease: progress in antiplatelet therapy.
Badimon L; Vilahur G
Rev Esp Cardiol; 2008 May; 61(5):501-13. PubMed ID: 18462654
[TBL] [Abstract][Full Text] [Related]
9. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population.
Faraday N; Becker DM; Yanek LR; Herrera-Galeano JE; Segal JB; Moy TF; Bray PF; Becker LC
Am J Cardiol; 2006 Sep; 98(6):774-9. PubMed ID: 16950183
[TBL] [Abstract][Full Text] [Related]
10. [Determination of the usefulness of selected biochemical parameters for assessing the advanced atheromatous changes in human coronary arteries].
Bukowska H
Ann Acad Med Stetin; 1998; 44():29-43. PubMed ID: 9857530
[TBL] [Abstract][Full Text] [Related]
11. Thrombogenesis and inhibition of platelet aggregation. Experimental aspects and future approaches.
Badimon L; Badimon JJ; Fuster V
Z Kardiol; 1990; 79 Suppl 3():133-45. PubMed ID: 2099036
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
Kowalski M
J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
[TBL] [Abstract][Full Text] [Related]
13. The use of clopidogrel in patients with coronary artery disease.
Cavuşoğlu E
Anadolu Kardiyol Derg; 2004 Mar; 4(1):63-72. PubMed ID: 15033622
[TBL] [Abstract][Full Text] [Related]
14. Coronary artery disease: pathogenesis and acute coronary syndromes.
Worthley SG; Osende JI; Helft G; Badimon JJ; Fuster V
Mt Sinai J Med; 2001 May; 68(3):167-81. PubMed ID: 11373689
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
Jennings LK
Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
[TBL] [Abstract][Full Text] [Related]
16. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
Kitai T; Nishikawa M; Tanigawa T; Okinaka T; Wada H; Shiku H; Ikeda Y; Ito M; Isaka N; Nakano T
Am Heart J; 2001 Aug; 142(2):E1. PubMed ID: 11479480
[TBL] [Abstract][Full Text] [Related]
17. The expanding role of antiplatelet agents in coronary artery disease. A current review of aspirin, glycoprotein IIb/IIIa inhibitors, and the thienopyridines.
Hostetter JC; Bhatt DL
Minerva Cardioangiol; 2003 Oct; 51(5):531-46. PubMed ID: 14551522
[TBL] [Abstract][Full Text] [Related]
18. Dietary fatty acids, hemostasis, and cardiovascular disease risk.
Lefevre M; Kris-Etherton PM; Zhao G; Tracy RP
J Am Diet Assoc; 2004 Mar; 104(3):410-9; quiz 492. PubMed ID: 14993864
[TBL] [Abstract][Full Text] [Related]
19. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M
Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cardiovascular events after acute coronary syndrome.
Wallentin L
Semin Vasc Med; 2005 Aug; 5(3):293-300. PubMed ID: 16123917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
